Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) will release its Q3 2022 financial results on November 3 after market close. Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and company updates. The Q3 earnings call will be accessible through the company's website. Syndax is focused on innovative cancer therapies, with key assets like revumenib and axatilimab in pivotal trials. Further information can be found on their website.

Positive

• Syndax is advancing its pipeline with revumenib and axatilimab in pivotal trials.

Negative

• None.

WALTHAM, Mass., Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2022 financial results and provide a business update on Thursday, November 3, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, November 3, 2022 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: SYNDAXQ3
Domestic Dial-in Number: 800-225-9448
International Dial-in Number: 203-518-9708
Live webcast: https://www.veracast.com/webcasts/OpenEx/General/S03S7x.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com 
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-november-3-2022-301660461.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals announce its Q3 2022 results?

Syndax Pharmaceuticals will announce its Q3 2022 financial results on November 3, 2022, after the close of the U.S. financial markets.

What time is the Syndax Q3 2022 earnings call?

The earnings call for Syndax Pharmaceuticals' Q3 2022 results is scheduled for 4:30 p.m. ET on November 3, 2022.

How can I access the Syndax Q3 2022 earnings call?

The Q3 2022 earnings call can be accessed via a live audio webcast on the company's website.

What are the key products in Syndax's pipeline?

Syndax's pipeline includes revumenib (SNDX-5613) and axatilimab, both of which are currently in pivotal trials.